Vaccines against Omicron approved for clinical trials
Two homegrown Omicron-specific COVID-19 vaccine candidates developed by Sinopharm and Sinovac Biotech have been approved for clinical trials by China's top drug regulator, the two companies said on Tuesday.
If the trial proceeds successfully, the experimental vaccine from Sinopharm will likely be used as a third or fourth booster shot for fully vaccinated people age 18 and older, the company said.
China National Biotech Group, a subsidiary of Sinopharm, said in a statement released on its website that the vaccine was already cleared for clinical trials in Hong Kong on April 13.